Taysha Gene (TSHA) showed a significant increase in its Q4 2024 EPS, with a value of $0.92 compared to $0.15 in the previous quarter, a 517% rise1. While this is a substantial improvement, it is important to note that TSHA's EPS was still lower than that of some industry peers. For instance, Biogen (BIIB) reported an EPS of $4 in Q4 2024, compared to $2.7 in the previous quarter, a 48% increase1. Similarly, Abbvie (ABBV) showed an EPS of $0.88 in Q4 2024, up from $0.77 in the previous quarter, a 15% increase1. Pepsico (PEP) demonstrated a more moderate increase in its EPS, with a value of $2.23 in Q4 2024, up from $2.13 in the previous quarter, a 5% rise1. Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) also had higher EPS values in Q4 2024, with $8.75 and $12.52 respectively1. Overall, while TSHA's EPS showed a strong improvement, it is still lower than that of some industry peers.
IONS, TSHA, BIIB, ABBV, PEP Diluted EPS
4/3/2025 09:11am
